arrow
S

Sunita D. Nasta

University of Pennsylvania
H指数:40
被引数:9,956

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Investigating Associations Between Psychological Distress and Changes in Peripheral Blood Monocytes in Patients With CLL/SLL Managed With Active Surveillance

探究心理困扰与接受主动监测的CLL/SLL患者外周血单核细胞变化之间的关联

2026-05-150
OAAI
Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Marginal Zone Lymphoma: Phase 1/2 BRUIN Study

Pirtobrutinib,R/R边缘区淋巴瘤中的高选择性,非共价 (可逆) BTKi: 1/2期布鲁因研究

2026-01-200
OAAI
PROs versus clinician-reported adverse events in a large clinical trial: findings from the Phase 3 POLARIX study

患者报告结果(PROs)与临床医生报告的不良事件在大型临床试验中的比较:来自III期POLARIX研究的结果

Blood
IF23.1
2025-09-290
OA
Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Follicular Lymphoma: Phase 1/2 BRUIN Study

Pirtobrutinib,一种高选择性、非共价(可逆)BTKi在复发/难治性滤泡性淋巴瘤中的应用:BRUIN研究1/2期

2025-08-250
OAAI
Retrospective cohort study of novel oral agents lenalidomide and duvelisib for relapsed or refractory mycosis fungoides and Sezary syndrome
2025-03-010
PRE
Prolonged Neurologic Symptoms Following Immune Effector Cell-Associated Neurotoxicity Syndrome in Patients With Large B-cell Lymphoma Treated With Chimeric Antigen Receptor-Modified T Cell Therapy

经嵌合抗原受体修饰的T细胞治疗的大b细胞淋巴瘤患者免疫效应细胞相关神经毒性综合征后神经系统症状延长

2025-01-010
PRE
Impact of Broad-Spectrum Antibiotic Exposure on CAR-T Therapy Outcomes in B-Cell Lymphoma: A Multicenter International Study

广谱抗生素暴露对B细胞淋巴瘤CAR-T治疗效果的影响:一项多中心国际研究

BLOOD
IF23.1
2024-11-050
PRE
Efficacy and Safety of Anti-CDI9 and Anti-BCMA Chimeric Antigen Receptor (CAR) T-Cell Therapies in Patients with Autoimmune Disease and Lymphoma or Myeloma

抗CDI9和抗BCMA嵌合抗原受体(CAR)T细胞疗法在自身免疫性疾病、淋巴瘤或骨髓瘤患者中的疗效与安全性

BLOOD
IF23.1
2024-11-050
PRE
Clinical Activity of Tisagenlecleucel in Large B Cell Lymphomas According to the 5 th Edition of the Who Classification

根据《世界卫生组织分类》第5版,tisagenlecleucel在大B细胞淋巴瘤中的临床活性

BLOOD
IF23.1
2024-11-050
PRE
Real-World Outcomes of Early Relapsed/Refractory Large B Cell Lymphoma Patients Treated with 2 nd Line CAR T Therapy

真实世界中接受2线CAR T治疗早期复发/难治性大B细胞淋巴瘤患者的临床结局

BLOOD
IF23.1
2024-11-050
PRE
The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas
2024-06-280
OAAI
Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel

苯达莫司汀用于利索卡塔烯前淋巴细胞耗竭的疗效和安全性

2024-04-220
OAAI
Immunologic Predictors of Vaccine Responsiveness in Patients With Lymphoma and Chronic Lymphocytic Leukemia

淋巴瘤和慢性淋巴细胞白血病患者疫苗反应性的免疫学预测指标

2024-03-042
PRE
Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines

苯达莫司汀在axicabtagene ciloleucel之前进行淋巴细胞耗竭是安全的,并且与减少的炎症细胞因子有关

2024-01-268
OAAI
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy

商业CAR T细胞治疗后T细胞淋巴瘤和继发性原发性恶性肿瘤风险

2024-01-2481
PRE